EQU-001 is under clinical development by Equilibre Biopharmaceuticals and currently in Phase II for Epilepsy. According to GlobalData, Phase II drugs for Epilepsy have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EQU-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EQU-001 is under development for the treatment of epilepsy and uncontrolled focal onset seizures (partial seizures). It is administered through oral route in the form of capsule.
Equilibre Biopharmaceuticals overview
Equilibre Biopharmaceuticals (Equilibre) is a biopharmaceutical company that discovers, develops and delivers treatments for neurodegenerative diseases. It is investigating drugs to treat nonepileptic and epileptic seizure disorders, traumatic brain injury, and spasticity associated with spinal cord injury. The company is also evaluating treatments for behavioural epileptic seizures (BES), Lennox-Gastaut, Dravent, CDKL5 deficiency syndrome and other epileptic encephalopathies. Equilibre is headquartered in New York, the US.
For a complete picture of EQU-001’s drug-specific PTSR and LoA scores, buy the report here.